Inhaled Insulin Offers New Hope for Diabetes Management

Managing diabetes has evolved significantly, and one of the latest advancements is the introduction of inhaled insulin. Afrezza, approved by the FDA for adults with type 1 and type 2 diabetes, serves as a fast-acting insulin option taken at mealtimes. However, it is essential to note that Afrezza does not replace the need for insulin altogether.

In a personal account, Melissa Pelayo, a 23-year-old student at the University of Arizona, reflects on her journey with diabetes. Diagnosed with type 1 diabetes after a lengthy process, Pelayo remembers feeling overwhelmed by the lifestyle changes required. “Initially they thought I was type 2. Then I got diagnosed with pre-diabetes. It was a whole hassle trying to find out what I have,” she explains.

Pelayo’s introduction to inhaled insulin came from her endocrinologist, Dr. Nora Barsony. She describes Afrezza as “a little tiny powder that goes right directly to the bloodstream through the lung.” The insulin begins to lower blood sugar levels approximately 12 minutes after ingestion, making it an effective solution for managing blood sugar spikes during meals.

Benefits and Considerations of Inhaled Insulin

One of the advantages of Afrezza is its rapid onset and quick elimination from the body. Dr. Barsony emphasizes its usefulness in emergencies, stating, “If you’re on the pump and your pump is failing, then get your little Afrezza.” This feature can be critical for those who rely on insulin pumps for daily management.

Despite its benefits, Afrezza is not suitable for everyone. Common side effects include coughing, and it is not recommended for smokers or individuals with chronic lung conditions such as asthma or chronic obstructive pulmonary disease (COPD). Additionally, Afrezza should not be used to treat diabetic ketoacidosis. For individuals with type 2 diabetes, there are specific requirements. “The patient has to be on a basal insulin,” Dr. Barsony clarifies.

According to a 2022 press release from the American Diabetes Association, over 37 million Americans, or about 11% of the population, live with diabetes, with 8.4 million relying on insulin for survival. Pelayo emphasizes the importance of embracing one’s diabetes journey, stating, “Having diabetes makes you unique. You have a new persona, right? It’s a new you, and just own it. Everyone is different.”

Dr. Barsony points out a limitation of Afrezza: the dosage units available for the inhaler do not match those used in traditional insulin injections. This aspect may affect the flexibility offered to patients. Nonetheless, she advocates for the option, noting that it enhances the ability for individuals to manage their health effectively.

Inhaled insulin represents a significant step forward in diabetes management, offering patients an alternative that combines convenience with efficacy. As advancements in treatment continue to evolve, options like Afrezza may help to improve the quality of life for those navigating the complexities of diabetes.